Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 2 Interventional Results available

Tocilizumab for the Treatment of Behcet's Syndrome

NCT01693653
Conditions
Behcet Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Heart Transplant
Interventions
tocilizumab, Placebo, Standard of Care Triple IS
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
26
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 22 more
Conditions
Dermatomyositis, Polymyositis
Interventions
tocilizumab, placebo
Drug
Lead sponsor
Chester Oddis
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Kansas City, Kansas • Rochester, Minnesota + 4 more
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
Conditions
Rheumatoid Arthritis
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
76
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more
Not listed Phase 1 Interventional

Tocilizumab in Schizophrenia

NCT02874573
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Tocilizumab, Normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more
Conditions
Arthritis, Rheumatoid
Interventions
Etanercept, Adalimumab, Upadacitinib, Tocilizumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
61
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
Conditions
COVID-19
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Major Depressive Disorder
Interventions
Tocilizumab, Placebo, Whole-Body Hyperthermia
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more
Completed Phase 1Phase 2 Interventional Results available

AIDS 347: IL-6 Blockade in Treated HIV Infection

NCT02049437
Conditions
HIV Infections
Interventions
tocilizumab, Placebo
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
155
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more
Conditions
Spondylitis, Ankylosing
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more
Conditions
Multiple Myeloma
Interventions
Ramantamig, Tocilizumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more
Conditions
Sclerosis, Systemic
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 18 more